Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.55 |
| ▸ | ARG2 | P78540 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | BHMT | Q93088 | 3/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23829637 | 1.00 | ARG1 (0.55) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL31711197 | 0.87 | NOS2 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL16059504 | 0.82 | ARG1 (0.56) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17361240 | 0.81 | ARG1 (0.69) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17361239 | 0.81 | ARG1 (0.69) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL119989 | 0.80 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL119988 | 0.80 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL16230008 | 0.80 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL27630394 | 0.80 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL31482265 | 0.78 | ARG1 (0.52) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024080323-A1 | SIRTUIN ACTIVATOR OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENESCENT CELL INHIBITOR | 湧永製薬株式会社 | 2024-04-18 | — | — | WO | disclosed |
| CN-117255681-A | Histone deacetylase or lansoprazole activation or expression enhancers, nad+ enhancers, and senescent cell inhibitors | 涌永制药株式会社 | 2023-12-19 | — | — | CN | disclosed |
| US-11717502-B2 | Blood flow improver | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-3308781-B1 | ANTIHYPERTENSIVE AGENT | WAKUNAGA PHARMA CO LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210228521-A1 | AUTOPHAGY ACTIVATING AGENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3804709-A1 | AUTOPHAGY ACTIVATING AGENT | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2021-04-14 | — | — | EP | disclosed |
| EP-3666269-A1 | BLOOD FLOW IMPROVER | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-20200147021-A1 | BLOOD FLOW IMPROVER | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-05-14 | — | — | US | disclosed |
| EP-3228312-B1 | IMMUNOREGULATOR | WAKUNAGA PHARMA CO LTD (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10363234-B2 | Antihypertensive agent | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-07-30 | — | — | US | disclosed |
| US-10238616-B2 | Immunomodulator | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| US-20180147170-A1 | ANTIHYPERTENSIVE AGENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-3308781-A1 | BLOOD PRESSURE-LOWERING AGENT | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20170360731-A1 | IMMUNOMODULATOR | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3228312-A1 | IMMUNOREGULATOR | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-6239111-B1 | DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0885608-A1 | REMEDIES FOR BRAIN DISEASES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147170-A1 | ANTIHYPERTENSIVE AGENT | AGTR1, GSTA1, REN | ARG1 737/4885ARG2 2047/4885NOS2 303/4885 |
| US-20200147021-A1 | BLOOD FLOW IMPROVER | GSR, GPX1, GSTA1 | ARG1 488/4885ARG2 517/4885NOS2 386/4885 |
| US-10238616-B2 | Immunomodulator | IMPA1, IDO1, MPEG1 | ARG1 25/4885ARG2 205/4885NOS2 1197/4885 |
| US-10363234-B2 | Antihypertensive agent | AGTR1, GSTA1, REN | ARG1 737/4885ARG2 2047/4885NOS2 303/4885 |
| US-11717502-B2 | Blood flow improver | GSR, GPX1, GSTA1 | ARG1 488/4885ARG2 517/4885NOS2 386/4885 |
| US-20210228521-A1 | AUTOPHAGY ACTIVATING AGENT | BECN1, ATG7, SQSTM1 | ARG1 1729/4885ARG2 814/4885NOS2 2123/4885 |
| US-20170360731-A1 | IMMUNOMODULATOR | IMPA1, IDO1, MPEG1 | ARG1 25/4885ARG2 205/4885NOS2 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.